Evidence map›Paper›PMID 38190417›Full record

ArticlePLoS genetics2024

SH2 domain protein E and ABL signaling regulate blood vessel size.

Jennifer A Schumacher, Zoë A Wright, Diandra Rufin Florat, Surendra K Anand, Manish Dasyani, Surya Prakash Rao Batta, Valentina Laverde, Kaitlin Ferrari, Laurita Klimkaite, Nina O Bredemeier and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. 1-L Transcription in Prion Diseases.International journal of molecular sciences · 2024
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Jennifer A SchumacherCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.
Zoë A WrightCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.
Diandra Rufin FloratUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.
Surendra K AnandUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.
Manish DasyaniCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.
Surya Prakash Rao BattaUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.
Valentina LaverdeUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.ORCID 0009-0009-8901-9982
Kaitlin FerrariUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.ORCID 0000-0001-8783-2106
Laurita KlimkaiteCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.ORCID 0000-0001-7090-0707
Nina O BredemeierCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.
Suman GurungUniversity of South Florida, Department of Pathology and Cell Biology, USF Health Heart Institute, Tampa, Florida, United States of America.
Gretchen M KollerUniversity of South Florida, Department of Molecular Pharmacology and Physiology, Tampa, Florida, United States of America.ORCID 0000-0001-6647-4071
Kalia N AgueraUniversity of South Florida, Department of Molecular Pharmacology and Physiology, Tampa, Florida, United States of America.ORCID 0000-0001-9701-7682
Griffin P ChadwickDepartment of Biological Sciences, Miami University, Hamilton, Ohio, United States of America.
Riley D JohnsonDepartment of Biological Sciences, Miami University, Hamilton, Ohio, United States of America.
George E DavisUniversity of South Florida, Department of Molecular Pharmacology and Physiology, Tampa, Florida, United States of America.ORCID 0000-0002-1549-1610
Saulius SumanasCincinnati Children's Hospital Medical Center, Division of Developmental Biology, Cincinnati, Ohio, United States of America.ORCID 0000-0002-8605-6122
University of South Florida · USCincinnati Children's Hospital Medical Center · USMiami University · US

Funding

Role of SHE and ABL signaling in vascular tubulogenesisR01HL163161 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Saulius Sumanas · 2023 to 2026
$2.6M
NHLBI NIH HHS R01 HL163161
6 · The paper itself

Abstract

Blood vessels in different vascular beds vary in size, which is essential for their function and fluid flow along the vascular network. Molecular mechanisms involved in the formation of a vascular lumen of appropriate size, or tubulogenesis, are still only partially understood. Src homology 2 domain containing E (She) protein was previously identified in a screen for proteins that interact with Abelson (Abl)-kinase. However, its biological role has remained unknown. Here we demonstrate that She and Abl signaling regulate vessel size in zebrafish embryos and human endothelial cell culture. Zebrafish she mutants displayed increased endothelial cell number and enlarged lumen size of the dorsal aorta (DA) and defects in blood flow, eventually leading to the DA collapse. Vascular endothelial specific overexpression of she resulted in a reduced diameter of the DA, which correlated with the reduced arterial cell number and lower endothelial cell proliferation. Chemical inhibition of Abl signaling in zebrafish embryos caused a similar reduction in the DA diameter and alleviated the she mutant phenotype, suggesting that She acts as a negative regulator of Abl signaling. Enlargement of the DA size in she mutants correlated with an increased endothelial expression of claudin 5a (cldn5a), which encodes a protein enriched in tight junctions. Inhibition of cldn5a expression partially rescued the enlarged DA in she mutants, suggesting that She regulates DA size, in part, by promoting cldn5a expression. SHE knockdown in human endothelial umbilical vein cells resulted in a similar increase in the diameter of vascular tubes, and also increased phosphorylation of a known ABL downstream effector CRKL. These results argue that SHE functions as an evolutionarily conserved inhibitor of ABL signaling and regulates vessel and lumen size during vascular tubulogenesis.

Indexed as

src Homology DomainsZebrafishAnimalsChinaClaudin-5EthnicityHumansSignal TransductionZebrafish ProteinsClaudin-5cldn5a protein, zebrafishZebrafish Proteins

Identifiers

PMID38190417
PMCPMC10798624
OpenAlexW4390660471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.